Detlef Schuppan

Detlef Schuppan

Auto-generated profile, based on publicly available information

Detlef Schuppan

Department of Medicine I, University of Erlangen-Nuernberg, Germany

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2001 in Seminars in Liver Disease
Verified
Journal Article
Closed access
PDF file
DSDetlef Schuppan
Detlef Schuppan
MRMartin Ruehl
Martin Ruehl
RSRajan Somasundaram
Rajan Somasundaram
EHEckhart G. Hahn
Eckhart G. Hahn
The extracellular matrix (ECM) provides cells with positional information and a mechanical scaffold for adhesion and migration. It consists of collagens, glycoproteins, proteoglycans, glycosaminoglycans and molecules that are bound specifically by the ECM, such as certain growth factors/cytokines, matrix metalloproteinases (MMPs) and processing enzymes such as tissue transglutaminase and procollagen propeptidases. This finely tuned ecosystem is dysbalanced in chronic fibrogenesis, which can be regarded as a continuous wound-healing process and which results in scar formation. Importantly, the ECM directs cellular differentiation, migration, proliferation, and fibrogenic activation or deactivation. Partially via defined oligopeptide sequences or structural domains, the ECM transfers specific signals to cells that act in concert with growth factors/cytokines. These signals either confer stress activation, with a resultant fibrogenic response, or stress relaxation, with a fibrolytic response. Alternatively, ECM-derived peptides can modulate angiogenesis, or growth factor and MMP availability and activity. Current ECM-related antifibrotic strategies are based on the identification and in vivo application of ECM-derived biomodulatory peptides, peptide sequences, or their nonpeptidic mimetics. The latter open the opportunity of oral application and an extended biological half-life. Examples are peptides derived from collagens VI (stress activation) and XIV (stress relaxation), or collagenous consensus peptides that remove ECM-bound MMPs and growth factors. Furthermore, certain peptides can be used as targeting structures to the fibrogenic lesion.

1 July 2000 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
DSDetlef Schuppan
Detlef Schuppan

1 January 2003 in Cell Death & Differentiation
Verified
Journal Article
Closed access
DSD Schuppan
D Schuppan
AKA Krebs
A Krebs
MBM Bauer
M Bauer
EHE G Hahn
E G Hahn

11 February 2002 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
CHC Herold
C Herold
MOM Ocker
M Ocker
MGM Ganslmayer
M Ganslmayer
HGH Gerauer
H Gerauer
EHE G Hahn
E G Hahn
DSD Schuppan
D Schuppan
Efficacy of chemotherapy in advanced stages of colorectal tumours is limited. The quinolone antibiotic ciprofloxacin was recently shown to inhibit growth and to induce apoptosis in human bladder carcinomas cells. We investigated the effect of ciprofloxacin on colon carcinoma lines in vitro. CC-531, SW-403 and HT-29 colon carcinoma and HepG2 hepatoma cells (control cells) were exposed to ciprofloxacin. Proliferation was assessed by bromodeoxyuridine-incorporation into DNA and apoptosis was measured by flow cytometry after propidium iodide or JC-1 staining. Expression of anti-apoptotic Bcl-2 and pro-apoptotic Bax was analyzed by semiquantitative Western blot analysis and activity of caspases 3, 8 and 9 by substrate-cleavage assays. Ciprofloxacin suppressed DNA synthesis of all colon carcinoma cells time- and dose-dependently, whereas the hepatoma cells remained unaffected. Apoptosis reached its maximum between 200 and 500 μg ml−1. This was accompanied by an upregulation of Bax and of the activity of caspases 3, 8 and 9, and paralleled by a decrease of the mitochondrial membrane potential. Ciprofloxacin decreases proliferation and induces apoptosis of colon carcinoma cells, possibly in part by blocking mitochondrial DNA synthesis. Therefore, qualification of ciprofloxacin as adjunctive agent for colorectal cancer should be evaluated.

1 February 2002 in Gut
Verified
Journal Article
Open access
PDF file
CRC Raetsch
C Raetsch
JJJ D Jia
J D Jia
GBG Boigk
G Boigk
MBM Bauer
M Bauer
EHE G Hahn
E G Hahn
DSD Schuppan
D Schuppan
Background: The trisubstituted methylxanthine derivative pentoxifylline inhibits hepatic stellate cell proliferation and collagen synthesis in vitro. The antifibrotic effect of pentoxifylline in a suitable in vivo model of chronic liver fibrogenesis remains to be tested. Methods: Groups of adult rats (n=20–23) received oral pentoxifylline at a dose of 8 mg/kg/day from week 1 to week 6, and 16 mg/kg/day from week 1 to week 6 or week 4 to week 6 after complete bile duct occlusion. Animals who underwent sham operation that received 16 mg/kg/day pentoxifylline and untreated rats with bile duct occlusion alone served as controls. After six weeks, animals were sacrificed and parameters of fibrogenesis determined. Results: Bile duct occlusion caused portal cirrhosis with a 10-fold increased hepatic collagen content in the absence of inflammation or necrosis. This was accompanied by an 11-fold elevated serum aminoterminal procollagen III peptide (PIIINP). The drug induced a dramatic eightfold downregulation of procollagen I mRNA, and suppression of the fibrogenic factors transforming growth factor β1 and connective tissue growth factor by 60–70%. However, profibrogenic tissue inhibitor of metalloproteinase 1 (TIMP-1) mRNA was increased twofold, resulting in only a moderate decrease in liver collagen, fibrosis score, and PIIINP. Conclusions: We conclude that targeting pentoxifylline to the fibrogenic cells, thereby avoiding upregulation of TIMP-1, could become a potent antifibrogenic tool in chronic liver disease.

1 October 2003
Verified
Journal Article
Closed access
TWThaddäus Till Wissniowski
Thaddäus Till Wissniowski
JHJohannes Hänsler
Johannes Hänsler
Daniel NeureiterDaniel Neureiter
Daniel Neureiter
MFMarkus Frieser
Markus Frieser
SSStefan Schaber
Stefan Schaber
JHJohannes Hünsler
Johannes Hünsler